Fixed Dose Drug Combinations–Are They Pharmacoeconomically Sound? Findings and Implications Especially for Lower- and Middle-Income Countries

Fixed Dose Drug Combinations–Are They Pharmacoeconomically Sound? Findings and Implications Especially for Lower- and Middle-Income Countries Publisher Pubmed

Godman B^{1, 2, 3, 4} ; Mccabe H⁵ ; Leong TD⁶ ; Mueller D^{7, 8} ; Martin AP^{9, 10} ; Hoxha I¹¹ ; Mwita JC¹² ; Rwegerera GM¹³ ; Massele A¹⁴ ; De Oliveira Costa J^{15, 16, 17} ; Do Nascimento RCRM^{1, 17} ; De Lemos LLP^{15, 16} ; Tachkov K¹⁸ ; Milushewa P¹⁹ Show All Authors

Godman B^{1, 2, 3, 4}
Mccabe H⁵
Leong TD⁶
Mueller D^{7, 8}
Martin AP^{9, 10}
Hoxha I¹¹
Mwita JC¹²
Rwegerera GM¹³
Massele A¹⁴
De Oliveira Costa J^{15, 16, 17}
Do Nascimento RCRM^{1, 17}
De Lemos LLP^{15, 16}
Tachkov K¹⁸
Milushewa P¹⁹
Patrick O^{20, 21}
Niba LL^{20, 22}
Laius O²³
Sefah I²⁴
Abdulsalim S²⁵
Soleymani F^{26, 27}
Guantai AN²⁸
Achieng L²⁹
Oluka M²⁹
Jakupi A³⁰
Logviss K³¹
Azmi Hassali M⁴
Kibuule D³²
Kalemeera F³²
Mubita M³²
Fadare J^{33, 34}
Ogunleye OO^{35, 36}
Saleem Z³⁷
Hussain S³⁸
Bochenek T³⁹
Mardare I⁴⁰
Alrasheedy AA⁴¹
Furst J⁴²
Tomek D⁴³
Markovicpekovic V⁴⁴
Rampamba EM^{2, 45}
Alfadl A^{42, 46}
Amu AA⁴⁷
Matsebula Z⁴⁸
Thi Phuong TN⁴⁹
Thanh BN⁴⁹
Kalungia AC⁵⁰
Zaranyika T⁵¹
Masuka N⁵²
Olaru ID^{53, 54}
Wale J⁵⁵
Hill R⁵⁶
Kurdi A^{1, 57}
Timoney A^{1, 58}
Campbell S^{59, 60}
Meyer JC²

Source: Expert Review of Pharmacoeconomics and Outcomes Research Published:2020

Abstract

Introduction: There are positive aspects regarding the prescribing of fixed dose combinations (FDCs) versus prescribing the medicines separately. However, these have to be balanced against concerns including increased costs and their irrationality in some cases. Consequently, there is a need to review their value among lower- and middle-income countries (LMICs) which have the greatest prevalence of both infectious and noninfectious diseases and issues of affordability. Areas covered: Review of potential advantages, disadvantages, cost-effectiveness, and availability of FDCs in high priority disease areas in LMICs and possible initiatives to enhance the prescribing of valued FDCs and limit their use where there are concerns with their value. Expert commentary: FDCs are valued across LMICs. Advantages include potentially improved response rates, reduced adverse reactions, increased adherence rates, and reduced costs. Concerns include increased chances of drug:drug interactions, reduced effectiveness, potential for imprecise diagnoses and higher unjustified prices. Overall certain FDCs including those for malaria, tuberculosis, and hypertension are valued and listed in the country’s essential medicine lists, with initiatives needed to enhance their prescribing where currently low prescribing rates. Proposed initiatives include robust clinical and economic data to address the current paucity of pharmacoeconomic data. Irrational FDCs persists in some countries which are being addressed. © 2020, © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

Related Docs

View other Related Docs

1. Cost-Effectiveness of Fixed-Dose Combination Pill (Polypill) in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Literature Review, PLoS ONE (2022)

2. Fixed Dose Combination Therapy for Secondary Prevention of Major Cardiovascular Events: Review of Literature and Design for Persian Polypill, a Randomized Clinical Trial, Current Problems in Cardiology (2022)

3. Variation in the Proportion of Adults in Need of Blood Pressure-Lowering Medications by Hypertension Care Guideline in Low- and Middle-Income Countries a Cross-Sectional Study of 1 037 215 Individuals From 50 Nationally Representative Surveys, Circulation (2021)

Experts (# of related papers)

View all Related Experts

Majid Davari (5)

Reza Malekzadeh (4)

Style	Citing Format
MLA	Godman B, et al.. "Fixed Dose Drug Combinations–Are They Pharmacoeconomically Sound? Findings and Implications Especially for Lower- and Middle-Income Countries." Expert Review of Pharmacoeconomics and Outcomes Research, vol. 20, no. 1, 2020, pp. 1-26.
APA	Godman B, Mccabe H, Leong TD, Mueller D, Martin AP, Hoxha I, Mwita JC, Rwegerera GM, Massele A, De Oliveira Costa J, Do Nascimento RCRM, De Lemos LLP, Tachkov K, Milushewa P, Patrick O, Niba LL, Laius O, Sefah I, Abdulsalim S, ... Meyer JC (2020). Fixed Dose Drug Combinations–Are They Pharmacoeconomically Sound? Findings and Implications Especially for Lower- and Middle-Income Countries. Expert Review of Pharmacoeconomics and Outcomes Research, 20(1), 1-26.
Chicago	Godman B, Mccabe H, Leong TD, Mueller D, Martin AP, Hoxha I, Mwita JC, et al.. "Fixed Dose Drug Combinations–Are They Pharmacoeconomically Sound? Findings and Implications Especially for Lower- and Middle-Income Countries." Expert Review of Pharmacoeconomics and Outcomes Research 20, no. 1 (2020): 1-26.
Harvard	Godman B et al. (2020) 'Fixed Dose Drug Combinations–Are They Pharmacoeconomically Sound? Findings and Implications Especially for Lower- and Middle-Income Countries', Expert Review of Pharmacoeconomics and Outcomes Research, 20(1), pp. 1-26.
Vancouver	Godman B, Mccabe H, Leong TD, Mueller D, Martin AP, Hoxha I, et al.. Fixed Dose Drug Combinations–Are They Pharmacoeconomically Sound? Findings and Implications Especially for Lower- and Middle-Income Countries. Expert Review of Pharmacoeconomics and Outcomes Research. 2020;20(1):1-26.
BibTex	@article{ author = {Godman B and Mccabe H and Leong TD and Mueller D and Martin AP and Hoxha I and Mwita JC and Rwegerera GM and Massele A and De Oliveira Costa J and Do Nascimento RCRM and De Lemos LLP and Tachkov K and Milushewa P and Patrick O and Niba LL and Laius O and Sefah I and Abdulsalim S and Soleymani F and Guantai AN and Achieng L and Oluka M and Jakupi A and Logviss K and Azmi Hassali M and Kibuule D and Kalemeera F and Mubita M and Fadare J and Ogunleye OO and Saleem Z and Hussain S and Bochenek T and Mardare I and Alrasheedy AA and Furst J and Tomek D and Markovicpekovic V and Rampamba EM and Alfadl A and Amu AA and Matsebula Z and Thi Phuong TN and Thanh BN and Kalungia AC and Zaranyika T and Masuka N and Olaru ID and Wale J and Hill R and Kurdi A and Timoney A and Campbell S and Meyer JC}, title = {Fixed Dose Drug Combinations–Are They Pharmacoeconomically Sound? Findings and Implications Especially for Lower- and Middle-Income Countries}, journal = {Expert Review of Pharmacoeconomics and Outcomes Research}, volume = {20}, number = {1}, pages = {1-26}, year = {2020} }
RIS	TY - JOUR AU - Godman B AU - Mccabe H AU - Leong TD AU - Mueller D AU - Martin AP AU - Hoxha I AU - Mwita JC AU - Rwegerera GM AU - Massele A AU - De Oliveira Costa J AU - Do Nascimento RCRM AU - De Lemos LLP AU - Tachkov K AU - Milushewa P AU - Patrick O AU - Niba LL AU - Laius O AU - Sefah I AU - Abdulsalim S AU - Soleymani F AU - Guantai AN AU - Achieng L AU - Oluka M AU - Jakupi A AU - Logviss K AU - Azmi Hassali M AU - Kibuule D AU - Kalemeera F AU - Mubita M AU - Fadare J AU - Ogunleye OO AU - Saleem Z AU - Hussain S AU - Bochenek T AU - Mardare I AU - Alrasheedy AA AU - Furst J AU - Tomek D AU - Markovicpekovic V AU - Rampamba EM AU - Alfadl A AU - Amu AA AU - Matsebula Z AU - Thi Phuong TN AU - Thanh BN AU - Kalungia AC AU - Zaranyika T AU - Masuka N AU - Olaru ID AU - Wale J AU - Hill R AU - Kurdi A AU - Timoney A AU - Campbell S AU - Meyer JC TI - Fixed Dose Drug Combinations–Are They Pharmacoeconomically Sound? Findings and Implications Especially for Lower- and Middle-Income Countries JO - Expert Review of Pharmacoeconomics and Outcomes Research VL - 20 IS - 1 SP - 1 EP - 26 PY - 2020 ER -

Style

Citing Format

MLA

Godman B, et al.. "Fixed Dose Drug Combinations–Are They Pharmacoeconomically Sound? Findings and Implications Especially for Lower- and Middle-Income Countries." Expert Review of Pharmacoeconomics and Outcomes Research, vol. 20, no. 1, 2020, pp. 1-26.

APA

Godman B, Mccabe H, Leong TD, Mueller D, Martin AP, Hoxha I, Mwita JC, Rwegerera GM, Massele A, De Oliveira Costa J, Do Nascimento RCRM, De Lemos LLP, Tachkov K, Milushewa P, Patrick O, Niba LL, Laius O, Sefah I, Abdulsalim S, ... Meyer JC (2020). Fixed Dose Drug Combinations–Are They Pharmacoeconomically Sound? Findings and Implications Especially for Lower- and Middle-Income Countries. Expert Review of Pharmacoeconomics and Outcomes Research, 20(1), 1-26.

Chicago

Godman B, Mccabe H, Leong TD, Mueller D, Martin AP, Hoxha I, Mwita JC, et al.. "Fixed Dose Drug Combinations–Are They Pharmacoeconomically Sound? Findings and Implications Especially for Lower- and Middle-Income Countries." Expert Review of Pharmacoeconomics and Outcomes Research 20, no. 1 (2020): 1-26.

Harvard

Godman B et al. (2020) 'Fixed Dose Drug Combinations–Are They Pharmacoeconomically Sound? Findings and Implications Especially for Lower- and Middle-Income Countries', Expert Review of Pharmacoeconomics and Outcomes Research, 20(1), pp. 1-26.

Vancouver

Godman B, Mccabe H, Leong TD, Mueller D, Martin AP, Hoxha I, et al.. Fixed Dose Drug Combinations–Are They Pharmacoeconomically Sound? Findings and Implications Especially for Lower- and Middle-Income Countries. Expert Review of Pharmacoeconomics and Outcomes Research. 2020;20(1):1-26.

BibTex

@article{ author = {Godman B and Mccabe H and Leong TD and Mueller D and Martin AP and Hoxha I and Mwita JC and Rwegerera GM and Massele A and De Oliveira Costa J and Do Nascimento RCRM and De Lemos LLP and Tachkov K and Milushewa P and Patrick O and Niba LL and Laius O and Sefah I and Abdulsalim S and Soleymani F and Guantai AN and Achieng L and Oluka M and Jakupi A and Logviss K and Azmi Hassali M and Kibuule D and Kalemeera F and Mubita M and Fadare J and Ogunleye OO and Saleem Z and Hussain S and Bochenek T and Mardare I and Alrasheedy AA and Furst J and Tomek D and Markovicpekovic V and Rampamba EM and Alfadl A and Amu AA and Matsebula Z and Thi Phuong TN and Thanh BN and Kalungia AC and Zaranyika T and Masuka N and Olaru ID and Wale J and Hill R and Kurdi A and Timoney A and Campbell S and Meyer JC}, title = {Fixed Dose Drug Combinations–Are They Pharmacoeconomically Sound? Findings and Implications Especially for Lower- and Middle-Income Countries}, journal = {Expert Review of Pharmacoeconomics and Outcomes Research}, volume = {20}, number = {1}, pages = {1-26}, year = {2020} }

RIS

TY - JOUR
AU - Godman B
AU - Mccabe H
AU - Leong TD
AU - Mueller D
AU - Martin AP
AU - Hoxha I
AU - Mwita JC
AU - Rwegerera GM
AU - Massele A
AU - De Oliveira Costa J
AU - Do Nascimento RCRM
AU - De Lemos LLP
AU - Tachkov K
AU - Milushewa P
AU - Patrick O
AU - Niba LL
AU - Laius O
AU - Sefah I
AU - Abdulsalim S
AU - Soleymani F
AU - Guantai AN
AU - Achieng L
AU - Oluka M
AU - Jakupi A
AU - Logviss K
AU - Azmi Hassali M
AU - Kibuule D
AU - Kalemeera F
AU - Mubita M
AU - Fadare J
AU - Ogunleye OO
AU - Saleem Z
AU - Hussain S
AU - Bochenek T
AU - Mardare I
AU - Alrasheedy AA
AU - Furst J
AU - Tomek D
AU - Markovicpekovic V
AU - Rampamba EM
AU - Alfadl A
AU - Amu AA
AU - Matsebula Z
AU - Thi Phuong TN
AU - Thanh BN
AU - Kalungia AC
AU - Zaranyika T
AU - Masuka N
AU - Olaru ID
AU - Wale J
AU - Hill R
AU - Kurdi A
AU - Timoney A
AU - Campbell S
AU - Meyer JC
TI - Fixed Dose Drug Combinations–Are They Pharmacoeconomically Sound? Findings and Implications Especially for Lower- and Middle-Income Countries
JO - Expert Review of Pharmacoeconomics and Outcomes Research
VL - 20
IS - 1
SP - 1
EP - 26
PY - 2020
ER -

Science Communicator Platform

Authors

Abstract